Xencor, Inc. (NASDAQ:XNCR) Shares Bought by Charles Schwab Investment Management Inc.

Charles Schwab Investment Management Inc. lifted its stake in shares of Xencor, Inc. (NASDAQ:XNCR - Free Report) by 7.0% during the third quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 626,988 shares of the biopharmaceutical company's stock after purchasing an additional 40,788 shares during the quarter. Charles Schwab Investment Management Inc. owned 0.90% of Xencor worth $12,609,000 as of its most recent SEC filing.

Several other large investors have also recently bought and sold shares of XNCR. Logos Global Management LP raised its stake in Xencor by 130.8% in the second quarter. Logos Global Management LP now owns 1,500,000 shares of the biopharmaceutical company's stock valued at $28,395,000 after purchasing an additional 850,000 shares in the last quarter. Point72 Asset Management L.P. lifted its holdings in shares of Xencor by 52.9% during the 2nd quarter. Point72 Asset Management L.P. now owns 1,261,789 shares of the biopharmaceutical company's stock worth $23,886,000 after acquiring an additional 436,389 shares during the last quarter. Essex LLC purchased a new position in Xencor in the third quarter worth $2,668,000. Dimensional Fund Advisors LP increased its stake in Xencor by 6.4% in the second quarter. Dimensional Fund Advisors LP now owns 1,459,427 shares of the biopharmaceutical company's stock valued at $27,628,000 after acquiring an additional 87,979 shares during the last quarter. Finally, Thrivent Financial for Lutherans raised its position in Xencor by 127.3% during the third quarter. Thrivent Financial for Lutherans now owns 116,369 shares of the biopharmaceutical company's stock valued at $2,340,000 after purchasing an additional 65,180 shares in the last quarter.

Xencor Price Performance

Shares of Xencor stock traded down $0.14 during trading on Monday, reaching $25.20. 393,595 shares of the stock were exchanged, compared to its average volume of 607,916. The company has a debt-to-equity ratio of 0.01, a quick ratio of 6.23 and a current ratio of 6.23. Xencor, Inc. has a 1 year low of $15.31 and a 1 year high of $27.24. The stock's fifty day moving average is $22.51 and its 200 day moving average is $20.60.

Xencor (NASDAQ:XNCR - Get Free Report) last released its quarterly earnings results on Wednesday, November 6th. The biopharmaceutical company reported ($0.71) earnings per share for the quarter, beating the consensus estimate of ($0.98) by $0.27. Xencor had a negative return on equity of 30.92% and a negative net margin of 232.77%. The company had revenue of $10.70 million for the quarter, compared to analyst estimates of $14.59 million. During the same period in the previous year, the company posted ($0.40) earnings per share. The firm's revenue was down 81.9% on a year-over-year basis. Sell-side analysts predict that Xencor, Inc. will post -3.71 earnings per share for the current fiscal year.

Insider Activity at Xencor

In related news, VP John R. Desjarlais sold 68,684 shares of the company's stock in a transaction dated Monday, November 11th. The shares were sold at an average price of $23.48, for a total transaction of $1,612,700.32. Following the completion of the sale, the vice president now owns 200,104 shares of the company's stock, valued at approximately $4,698,441.92. This represents a 25.55 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Alan Bruce Montgomery sold 13,301 shares of Xencor stock in a transaction on Monday, December 2nd. The stock was sold at an average price of $27.03, for a total value of $359,526.03. Following the transaction, the director now owns 9,140 shares in the company, valued at approximately $247,054.20. This represents a 59.27 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 136,050 shares of company stock worth $3,277,609. 5.23% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

A number of brokerages recently weighed in on XNCR. BMO Capital Markets reissued an "outperform" rating and set a $34.00 price objective (up from $32.00) on shares of Xencor in a report on Friday, November 8th. Royal Bank of Canada lifted their price target on shares of Xencor from $31.00 to $34.00 and gave the stock an "outperform" rating in a research note on Thursday, September 26th. Piper Sandler raised shares of Xencor from a "neutral" rating to an "overweight" rating and upped their price objective for the company from $20.00 to $30.00 in a research note on Monday, December 2nd. Wedbush reiterated an "outperform" rating and issued a $38.00 target price on shares of Xencor in a research report on Thursday, November 7th. Finally, JPMorgan Chase & Co. upped their price target on shares of Xencor from $27.00 to $28.00 and gave the company an "overweight" rating in a research report on Thursday, November 7th. One equities research analyst has rated the stock with a hold rating, seven have given a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat.com, the company currently has an average rating of "Buy" and an average target price of $36.50.

Xencor Company Profile

Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.